Larkberget

Larkberget EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Larkberget (LARK.ST) as of Oct 16, 2026 is -3.35. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 0.84 — a change of -501.25% (lower).

EV/OCF

-3.35

YoY

-501.25%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Larkberget is 2025 -3.35 . EV/OCF (Enterprise Value to Operating Cash Flow) of Larkberget was 2024 0.84 . It decreases by -501.25% lower compared to the previous year.

The Larkberget EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2018
74.28 SEK
Jan 1, 2019
-1.97 SEK
Jan 1, 2020
0.00 SEK
Jan 1, 2021
-3.98 SEK
Jan 1, 2022
4.98 SEK
Jan 1, 2023
1.73 SEK
Jan 1, 2024
0.84 SEK
Jan 1, 2025
-3.35 SEK
The Larkberget EV/OCF history
YEAREV/OCFYoY
-3.35-501.25%
0.84-51.55%
1.73-65.38%
4.98-225.21%
-3.98-82,923.21%
0.00-100.24%
-1.97-102.65%
74.28-1,716.04%
-4.60-11.32%
-5.18-17.18%
-6.26-91.07%
-70.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Larkberget Stock analysis

What does Larkberget do? Larkberget AB, trading under the ticker LARK.ST, is a biotechnology company based in Lidingoe, Sweden. The company, which is listed on the Stockholm Stock Exchange, went public through an IPO on May 25, 2015. Larkberget AB operates within the health care sector, specifically in the biotechnology industry. The company's website is https://combigene.com/. According to the provided information, Larkberget AB is engaged in the development of new treatments for neurological diseases. The firm's platform involves the use of gene therapy vectors to deliver combinations of transgenes encoding neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors. These vectors are designed for the treatment of neurological and psychiatric diseases in both humans and animals. The company focuses on developing an epilepsy treatment using an adeno-associated virus (AAV) vector that carries transgenes for the neurotransmitter NPY and its receptor, the G protein-coupled receptor Y2. The company's headquarters are located in Lidingoe, near Stockholm. Larkberget is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Larkberget stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Larkberget is -3.35 in 2025.

EV/OCF (Enterprise Value to Operating Cash Flow) of Larkberget changed from 0.84 to -3.35, representing a -501.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Larkberget since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Larkberget with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Larkberget

All Key Metrics — Larkberget